» Articles » PMID: 30577564

Enhancement of Aqueous Solubility and Dissolution of Celecoxib Through Phosphatidylcholine-Based Dispersion Systems Solidified with Adsorbent Carriers

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2018 Dec 23
PMID 30577564
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

This study aimed to design phosphatidylcholine (PC)-based solid dispersion (SD) systems for enhancing the apparent aqueous solubility and dissolution of celecoxib (CLC), a selective cyclooxygenase-2 inhibitor with a highly hydrophobic property. Although PC-based dispersion formulations considerably increased solubilities of CLC, the lipidic texture of PC was not appropriate as a solid dosage form for oral administration of CLC. To mask the lipidic texture of PC-based matrices, Neusilin US2, an adsorbent material with a porous structure and large surface area widely used in the pharmaceutical industry, was employed and thereby fully powderized PC-based dispersion formulations could be fabricated. However, PC matrices containing CLC strongly adsorbed to the pores of Neusilin US2 was not able to be rapidly released. To address this problem, different hydrophilic materials were examined to promote the release of the CLC-dispersed PC matrices from Neusilin US2. Among tested hydrophilic materials, croscarmellose sodium was the most suitable to facilitate fast drug dissolution from Neusilin US2 particles, showing significantly enhanced apparent aqueous solubility and dissolution behavior of CLC. Through differential scanning calorimetry, X-ray diffraction, and Fourier transform infrared spectroscopy (FT-IR) analysis, a considerably reduced crystallinity of CLC dispersed in the PC-based dispersion formulations was demonstrated. The PC-based SD formulations developed in this study would be useful for improving the oral bioavailability of poorly soluble drugs such as CLC.

Citing Articles

Application of the Box-Behnken Design in the Development of Amorphous PVP K30-Phosphatidylcholine Dispersions for the Co-Delivery of Curcumin and Hesperetin Prepared by Hot-Melt Extrusion.

Wdowiak K, Tajber L, Miklaszewski A, Cielecka-Piontek J Pharmaceutics. 2025; 17(1).

PMID: 39861675 PMC: 11768460. DOI: 10.3390/pharmaceutics17010026.


An update on selective estrogen receptor modulator: repurposing and formulations.

Patel R, James V, Prajapati B Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39820645 DOI: 10.1007/s00210-024-03753-w.


Investigation of magnesium aluminometasilicate (Neusilin US2) based surface solid dispersion of sorafenib tosylate using QbD approach: and pharmacokinetic study.

Panda B, Chellampillai B, Ghodake S, Mali A, Kamble R ADMET DMPK. 2024; 12(4):687-702.

PMID: 39473622 PMC: 11517514. DOI: 10.5599/admet.2338.


Amorphous Polymer-Phospholipid Solid Dispersions for the Co-Delivery of Curcumin and Piperine Prepared via Hot-Melt Extrusion.

Wdowiak K, Miklaszewski A, Cielecka-Piontek J Pharmaceutics. 2024; 16(8).

PMID: 39204344 PMC: 11359794. DOI: 10.3390/pharmaceutics16080999.


Co-Dispersion Delivery Systems with Solubilizing Carriers Improving the Solubility and Permeability of Cannabinoids (Cannabidiol, Cannabidiolic Acid, and Cannabichromene) from (Henola Variety) Inflorescences.

Stasilowicz-Krzemien A, Szulc P, Cielecka-Piontek J Pharmaceutics. 2023; 15(9).

PMID: 37765249 PMC: 10537421. DOI: 10.3390/pharmaceutics15092280.


References
1.
Serajuddin A . Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci. 1999; 88(10):1058-66. DOI: 10.1021/js980403l. View

2.
Paulson S, Vaughn M, Jessen S, Lawal Y, Gresk C, Yan B . Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther. 2001; 297(2):638-45. View

3.
Seedher N, Bhatia S . Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech. 2003; 4(3):E33. PMC: 2750626. DOI: 10.1208/pt040333. View

4.
Reddy M, Rehana T, Ramakrishna S, Chowdhary K, Diwan P . Beta-cyclodextrin complexes of celecoxib: molecular-modeling, characterization, and dissolution studies. AAPS PharmSci. 2004; 6(1):E7. PMC: 2750942. DOI: 10.1208/ps060107. View

5.
Gupta P, Kakumanu V, Bansal A . Stability and solubility of celecoxib-PVP amorphous dispersions: a molecular perspective. Pharm Res. 2004; 21(10):1762-9. DOI: 10.1023/b:pham.0000045226.42859.b8. View